Reducing the harms of xylazine: clinical approaches, research deficits, and public health context

Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine's harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine's public health and policy context. As an interdiscip...

Full description

Saved in:
Bibliographic Details
Published inHarm reduction journal Vol. 20; no. 1; pp. 141 - 9
Main Authors Zagorski, Claire M., Hosey, Rebecca A., Moraff, Christopher, Ferguson, Aaron, Figgatt, Mary, Aronowitz, Shoshana, Stahl, Natalie E., Hill, Lucas G., McElligott, Zoe, Dasgupta, Nabarun
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 30.09.2023
BioMed Central
BMC
Subjects
Anemia
Anesthesia
Benzodiazepines
Blood pressure
Case reports
Community involvement
Community participation
Complications and side effects
Dosage and administration
Drug injection
Drug withdrawal
Drugs
Epidemiology
Fatalities
Fentanyl
Harm Reduction
Health aspects
Heroin
Humans
Hyperglycemia
Hypertension
Management
Medical personnel
Methods
Narcotics
Poisoning
Public Health
Public participation
Reduction
Sex crimes
Surveillance
Veterinary drugs
Veterinary medicine
Wounds
Xylazine
Xylazine - therapeutic use
United States
Drug injection
Harm reduction
Wounds
Xylazine
Online AccessGet full text

Cover

Abstract Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine's harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine's public health and policy context. As an interdisciplinary team from across the USA, we have pooled our knowledge to provide an overview of xylazine's current and emerging contexts. To inform this essay, the pertinent literature was reviewed, clinical knowledge and protocols were shared by multiple clinicians with direct expertise, and policy and public health context were added by expert authors. We describe xylazine's major harm domains-acute poisoning, extended sedation, and wounds, along with anemia and hyperglycemia, which have been reported anecdotally but lack as clear of a connection to xylazine. Current successful practices for xylazine wound care are detailed. Understanding xylazine's epidemiology will also require greater investment in drug checking and surveillance. Finally, approaches to community-based wound care are discussed, along with an orientation to the larger policy and public health context. Addressing the harms of xylazine requires interdisciplinary participation, investment in community-based harm reduction strategies, and improved drug supply surveillance. The relatively unique context of xylazine demands buy-in from public health professionals, harm reduction professionals, clinicians, basic science researchers, policymakers and more.
AbstractList Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine's harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine's public health and policy context. As an interdisciplinary team from across the USA, we have pooled our knowledge to provide an overview of xylazine's current and emerging contexts. To inform this essay, the pertinent literature was reviewed, clinical knowledge and protocols were shared by multiple clinicians with direct expertise, and policy and public health context were added by expert authors. We describe xylazine's major harm domains--acute poisoning, extended sedation, and wounds, along with anemia and hyperglycemia, which have been reported anecdotally but lack as clear of a connection to xylazine. Current successful practices for xylazine wound care are detailed. Understanding xylazine's epidemiology will also require greater investment in drug checking and surveillance. Finally, approaches to community-based wound care are discussed, along with an orientation to the larger policy and public health context. Addressing the harms of xylazine requires interdisciplinary participation, investment in community-based harm reduction strategies, and improved drug supply surveillance. The relatively unique context of xylazine demands buy-in from public health professionals, harm reduction professionals, clinicians, basic science researchers, policymakers and more.
ObjectivesXylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine’s harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine’s public health and policy context. As an interdisciplinary team from across the USA, we have pooled our knowledge to provide an overview of xylazine’s current and emerging contexts.MethodsTo inform this essay, the pertinent literature was reviewed, clinical knowledge and protocols were shared by multiple clinicians with direct expertise, and policy and public health context were added by expert authors.ResultsWe describe xylazine’s major harm domains—acute poisoning, extended sedation, and wounds, along with anemia and hyperglycemia, which have been reported anecdotally but lack as clear of a connection to xylazine. Current successful practices for xylazine wound care are detailed. Understanding xylazine’s epidemiology will also require greater investment in drug checking and surveillance. Finally, approaches to community-based wound care are discussed, along with an orientation to the larger policy and public health context.ConclusionsAddressing the harms of xylazine requires interdisciplinary participation, investment in community-based harm reduction strategies, and improved drug supply surveillance. The relatively unique context of xylazine demands buy-in from public health professionals, harm reduction professionals, clinicians, basic science researchers, policymakers and more.
Abstract Objectives Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine’s harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine’s public health and policy context. As an interdisciplinary team from across the USA, we have pooled our knowledge to provide an overview of xylazine’s current and emerging contexts. Methods To inform this essay, the pertinent literature was reviewed, clinical knowledge and protocols were shared by multiple clinicians with direct expertise, and policy and public health context were added by expert authors. Results We describe xylazine’s major harm domains—acute poisoning, extended sedation, and wounds, along with anemia and hyperglycemia, which have been reported anecdotally but lack as clear of a connection to xylazine. Current successful practices for xylazine wound care are detailed. Understanding xylazine’s epidemiology will also require greater investment in drug checking and surveillance. Finally, approaches to community-based wound care are discussed, along with an orientation to the larger policy and public health context. Conclusions Addressing the harms of xylazine requires interdisciplinary participation, investment in community-based harm reduction strategies, and improved drug supply surveillance. The relatively unique context of xylazine demands buy-in from public health professionals, harm reduction professionals, clinicians, basic science researchers, policymakers and more.
Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine's harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine's public health and policy context. As an interdisciplinary team from across the USA, we have pooled our knowledge to provide an overview of xylazine's current and emerging contexts.OBJECTIVESXylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine's harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine's public health and policy context. As an interdisciplinary team from across the USA, we have pooled our knowledge to provide an overview of xylazine's current and emerging contexts.To inform this essay, the pertinent literature was reviewed, clinical knowledge and protocols were shared by multiple clinicians with direct expertise, and policy and public health context were added by expert authors.METHODSTo inform this essay, the pertinent literature was reviewed, clinical knowledge and protocols were shared by multiple clinicians with direct expertise, and policy and public health context were added by expert authors.We describe xylazine's major harm domains-acute poisoning, extended sedation, and wounds, along with anemia and hyperglycemia, which have been reported anecdotally but lack as clear of a connection to xylazine. Current successful practices for xylazine wound care are detailed. Understanding xylazine's epidemiology will also require greater investment in drug checking and surveillance. Finally, approaches to community-based wound care are discussed, along with an orientation to the larger policy and public health context.RESULTSWe describe xylazine's major harm domains-acute poisoning, extended sedation, and wounds, along with anemia and hyperglycemia, which have been reported anecdotally but lack as clear of a connection to xylazine. Current successful practices for xylazine wound care are detailed. Understanding xylazine's epidemiology will also require greater investment in drug checking and surveillance. Finally, approaches to community-based wound care are discussed, along with an orientation to the larger policy and public health context.Addressing the harms of xylazine requires interdisciplinary participation, investment in community-based harm reduction strategies, and improved drug supply surveillance. The relatively unique context of xylazine demands buy-in from public health professionals, harm reduction professionals, clinicians, basic science researchers, policymakers and more.CONCLUSIONSAddressing the harms of xylazine requires interdisciplinary participation, investment in community-based harm reduction strategies, and improved drug supply surveillance. The relatively unique context of xylazine demands buy-in from public health professionals, harm reduction professionals, clinicians, basic science researchers, policymakers and more.
Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine's harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine's public health and policy context. As an interdisciplinary team from across the USA, we have pooled our knowledge to provide an overview of xylazine's current and emerging contexts. To inform this essay, the pertinent literature was reviewed, clinical knowledge and protocols were shared by multiple clinicians with direct expertise, and policy and public health context were added by expert authors. We describe xylazine's major harm domains-acute poisoning, extended sedation, and wounds, along with anemia and hyperglycemia, which have been reported anecdotally but lack as clear of a connection to xylazine. Current successful practices for xylazine wound care are detailed. Understanding xylazine's epidemiology will also require greater investment in drug checking and surveillance. Finally, approaches to community-based wound care are discussed, along with an orientation to the larger policy and public health context. Addressing the harms of xylazine requires interdisciplinary participation, investment in community-based harm reduction strategies, and improved drug supply surveillance. The relatively unique context of xylazine demands buy-in from public health professionals, harm reduction professionals, clinicians, basic science researchers, policymakers and more.
Objectives Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine's harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine's public health and policy context. As an interdisciplinary team from across the USA, we have pooled our knowledge to provide an overview of xylazine's current and emerging contexts. Methods To inform this essay, the pertinent literature was reviewed, clinical knowledge and protocols were shared by multiple clinicians with direct expertise, and policy and public health context were added by expert authors. Results We describe xylazine's major harm domains--acute poisoning, extended sedation, and wounds, along with anemia and hyperglycemia, which have been reported anecdotally but lack as clear of a connection to xylazine. Current successful practices for xylazine wound care are detailed. Understanding xylazine's epidemiology will also require greater investment in drug checking and surveillance. Finally, approaches to community-based wound care are discussed, along with an orientation to the larger policy and public health context. Conclusions Addressing the harms of xylazine requires interdisciplinary participation, investment in community-based harm reduction strategies, and improved drug supply surveillance. The relatively unique context of xylazine demands buy-in from public health professionals, harm reduction professionals, clinicians, basic science researchers, policymakers and more. Keywords: Xylazine, Harm reduction, Wounds, Drug injection
ArticleNumber 141
Audience Academic
Author Moraff, Christopher
Zagorski, Claire M.
Hill, Lucas G.
Hosey, Rebecca A.
McElligott, Zoe
Aronowitz, Shoshana
Figgatt, Mary
Stahl, Natalie E.
Dasgupta, Nabarun
Ferguson, Aaron
Author_xml – sequence: 1
  givenname: Claire M.
  surname: Zagorski
  fullname: Zagorski, Claire M.
– sequence: 2
  givenname: Rebecca A.
  surname: Hosey
  fullname: Hosey, Rebecca A.
– sequence: 3
  givenname: Christopher
  surname: Moraff
  fullname: Moraff, Christopher
– sequence: 4
  givenname: Aaron
  surname: Ferguson
  fullname: Ferguson, Aaron
– sequence: 5
  givenname: Mary
  surname: Figgatt
  fullname: Figgatt, Mary
– sequence: 6
  givenname: Shoshana
  surname: Aronowitz
  fullname: Aronowitz, Shoshana
– sequence: 7
  givenname: Natalie E.
  surname: Stahl
  fullname: Stahl, Natalie E.
– sequence: 8
  givenname: Lucas G.
  surname: Hill
  fullname: Hill, Lucas G.
– sequence: 9
  givenname: Zoe
  surname: McElligott
  fullname: McElligott, Zoe
– sequence: 10
  givenname: Nabarun
  surname: Dasgupta
  fullname: Dasgupta, Nabarun
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37777769$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1rFDEUhgep2Hb1D3ghA9544dRJMklmvCml-FEoCKLX4UxyZidLNlmTGWn99WZ3a-0WMSEknDznDefkPS2OfPBYFC9JfUZIK94lQjveVDVlVV23sqvkk-KENFJWkhN59OB8XJymtKrrzLP2WXHM5HaI7qSAr2hmbf2ynEYsR4jrVIahvLl18Mt6fF9qZ73V4ErYbGIAPWJ6W0ZMCFGPpcHBajvlEHhTbubeWV2OCG4aSx38hDfT8-LpAC7hi7t9UXz_-OHb5efq-sunq8uL60pz0UwVpxoN41wbqoeOIQUgjBEpZJ-jjCOXRAimWSNbbUBIQ_pOcEk71pKBcrYorva6JsBKbaJdQ7xVAazaBUJcKoiT1Q7VQAV0rekFM33T67rXhiOTBoYBNEORtc73WrmiNRqNforgDkQPb7wd1TL8VKTmTUMkywpv7hRi-DFjmtTaJo3OgccwJ0VbWXcda_JaFK8foaswR597taVkRgRt_1JLyBVYP4T8sN6KqovcJCprsXv27B9UngbXNn9I_q4cP0h49bDS-xL_OCQDdA_oGFKKONwjpFZbG6q9DVW2odrZUMmc1D5KyiaByYZtt6z7X-pvuYngow
CitedBy_id crossref_primary_10_1186_s12954_024_00940_z
crossref_primary_10_1016_j_addicn_2024_100155
crossref_primary_10_1016_j_outlook_2024_102248
crossref_primary_10_1177_29767342241289797
crossref_primary_10_1177_29767342231214472
crossref_primary_10_2196_56755
crossref_primary_10_3390_toxics11121012
crossref_primary_10_1016_j_jen_2024_06_001
crossref_primary_10_1080_10826084_2024_2409720
crossref_primary_10_1186_s12954_024_01097_5
crossref_primary_10_1016_j_drugpo_2024_104517
crossref_primary_10_1097_ADM_0000000000001431
crossref_primary_10_1016_j_drugpo_2025_104716
crossref_primary_10_1016_j_drugpo_2024_104338
crossref_primary_10_1016_j_dadr_2024_100247
crossref_primary_10_1016_j_drugalcdep_2024_112390
crossref_primary_10_1186_s12954_023_00903_w
crossref_primary_10_1016_j_amepre_2024_05_005
crossref_primary_10_2174_0122106766304121240718112939
crossref_primary_10_1186_s12954_024_00959_2
crossref_primary_10_1080_10550887_2024_2391156
crossref_primary_10_1097_ADM_0000000000001352
crossref_primary_10_3390_app15063410
crossref_primary_10_3390_psychoactives3010009
crossref_primary_10_1186_s12954_024_01143_2
crossref_primary_10_1016_j_drugpo_2024_104588
crossref_primary_10_1021_acschemneuro_4c00172
crossref_primary_10_1016_j_drugpo_2024_104587
crossref_primary_10_1080_10826084_2024_2393220
Cites_doi 10.1097/ADM.0000000000000955
10.1007/s00421-021-04764-8
10.2105/AJPH.2022.306881
10.1186/1471-2253-13-33
10.1097/00129334-200604000-00011
10.1016/j.drugpo.2019.10.004
10.1093/cid/ciq146
10.1101/2023.09.08.556914
10.1016/j.drugalcdep.2006.10.014
10.1016/j.tcr.2017.09.002
10.1080/09595230802089701
10.1111/wrr.12117
10.1186/s12954-021-00528-x
10.1136/pmj.76.899.561
10.1186/s12954-020-00372-5
10.31389/jied.122
10.1097/01.ASW.0000428861.26671.41
10.1111/jvp.12724
10.1111/bcp.12731
10.1016/j.drugalcdep.2008.03.005
10.1016/j.idc.2020.10.006
10.1016/j.drugpo.2017.05.050
10.1089/wound.2020.1243
10.1016/j.drugalcdep.2019.01.037
10.1111/j.1365-2885.1988.tb00189.x
10.1007/s11524-011-9662-6
10.1016/j.forsciint.2014.03.015
10.1016/j.drugalcdep.2022.109380
10.1093/aje/kwab233
10.12968/bjon.2018.27.18.1050
10.2344/0003-3006-62.1.31
10.11606/issn.2318-3659.v49i2p139-145
10.1016/j.jaad.2015.08.070
10.1080/15563650.2022.2063135
ContentType Journal Article
Copyright 2023. BioMed Central Ltd., part of Springer Nature.
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
BioMed Central Ltd., part of Springer Nature 2023
Copyright_xml – notice: 2023. BioMed Central Ltd., part of Springer Nature.
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: BioMed Central Ltd., part of Springer Nature 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ATCPS
AZQEC
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
M0S
M1P
PATMY
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PYCSY
7X8
5PM
DOA
DOI 10.1186/s12954-023-00879-7
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Agricultural & Environmental Science Collection
ProQuest Central Essentials
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Environmental Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Environmental Science Collection
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Agricultural & Environmental Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Environmental Science Collection
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Social Welfare & Social Work
Public Health
Veterinary Medicine
EISSN 1477-7517
EndPage 9
ExternalDocumentID oai_doaj_org_article_f26a98db63db4bc0bcd5e37daffac3e6
PMC10544173
A767270673
37777769
10_1186_s12954_023_00879_7
Genre Journal Article
Review
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: F31 DA055345
GroupedDBID ---
0R~
29I
2WC
2XV
53G
5GY
5VS
7X7
7XC
88E
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACHQT
ACIHN
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
ATCPS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
IPY
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PATMY
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PYCSY
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c564t-52ced355cd2cf93e2aa1331767b35535e571663c3478cda67d1b965729381f253
IEDL.DBID M48
ISSN 1477-7517
IngestDate Wed Aug 27 01:30:06 EDT 2025
Thu Aug 21 18:36:13 EDT 2025
Thu Jul 10 19:12:08 EDT 2025
Sat Aug 23 13:16:02 EDT 2025
Tue Jun 17 22:26:08 EDT 2025
Tue Jun 10 21:24:43 EDT 2025
Sun Jul 20 01:30:23 EDT 2025
Tue Jul 01 00:47:01 EDT 2025
Thu Apr 24 22:52:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Drug injection
Harm reduction
Wounds
Xylazine
Language English
License 2023. BioMed Central Ltd., part of Springer Nature.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-52ced355cd2cf93e2aa1331767b35535e571663c3478cda67d1b965729381f253
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12954-023-00879-7
PMID 37777769
PQID 2877499628
PQPubID 105462
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_f26a98db63db4bc0bcd5e37daffac3e6
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10544173
proquest_miscellaneous_2870993499
proquest_journals_2877499628
gale_infotracmisc_A767270673
gale_infotracacademiconefile_A767270673
pubmed_primary_37777769
crossref_primary_10_1186_s12954_023_00879_7
crossref_citationtrail_10_1186_s12954_023_00879_7
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-09-30
PublicationDateYYYYMMDD 2023-09-30
PublicationDate_xml – month: 09
  year: 2023
  text: 2023-09-30
  day: 30
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Harm reduction journal
PublicationTitleAlternate Harm Reduct J
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References HF Chambers (879_CR24) 2021; 35
SA Greene (879_CR1) 1988; 11
K Ruiz-Colon (879_CR4) 2014; 240
879_CR8
879_CR9
879_CR11
879_CR6
879_CR10
879_CR32
G Kolla (879_CR38) 2020; 17
879_CR30
C Liu (879_CR31) 2011; 52
Z Hoda (879_CR34) 2008; 27
AR Mackenzie (879_CR33) 2000; 76
879_CR19
879_CR18
G Brown (879_CR28) 2006; 19
MC Figgatt (879_CR13) 2021; 18
NS Ball (879_CR14) 2022; 60
J Ahern (879_CR12) 2007; 88
DP Sanchez (879_CR37) 2021; 10
J Majtan (879_CR29) 2014; 22
J Friedman (879_CR15) 2022; 233
D Clarke (879_CR22) 2017; 11
ML Sivilotti (879_CR16) 2016; 81
J Powers (879_CR26) 2016; 74
RG Wilkins (879_CR27) 2013; 26
N Dasgupta (879_CR39) 2022; 191
879_CR20
RS Alexander (879_CR7) 2022; 112
879_CR41
879_CR40
JC Reyes (879_CR5) 2012; 89
DL Biancarelli (879_CR25) 2019; 198
A Abbey (879_CR23) 2001; 25
P Ramondou (879_CR21) 2021; 121
AM Ambrosio (879_CR35) 2012; 49
L Beletsky (879_CR42) 2017; 46
JA Giovannitti (879_CR17) 2015; 62
T Kitano (879_CR2) 2019; 42
879_CR3
YF Xiao (879_CR36) 2013; 13
38012764 - Harm Reduct J. 2023 Nov 27;20(1):170. doi: 10.1186/s12954-023-00903-w.
References_xml – ident: 879_CR18
  doi: 10.1097/ADM.0000000000000955
– ident: 879_CR32
– volume: 121
  start-page: 3031
  issue: 11
  year: 2021
  ident: 879_CR21
  publication-title: Eur J Appl Physiol
  doi: 10.1007/s00421-021-04764-8
– ident: 879_CR30
– volume: 112
  start-page: 1212
  issue: 8
  year: 2022
  ident: 879_CR7
  publication-title: Am J Public Health
  doi: 10.2105/AJPH.2022.306881
– volume: 13
  start-page: 33
  issue: 1
  year: 2013
  ident: 879_CR36
  publication-title: BMC Anesthesiol
  doi: 10.1186/1471-2253-13-33
– volume: 19
  start-page: 155
  issue: 3
  year: 2006
  ident: 879_CR28
  publication-title: Adv Skin Wound Care
  doi: 10.1097/00129334-200604000-00011
– ident: 879_CR11
  doi: 10.1016/j.drugpo.2019.10.004
– volume: 52
  start-page: e18
  issue: 3
  year: 2011
  ident: 879_CR31
  publication-title: Clin infect Dis.
  doi: 10.1093/cid/ciq146
– ident: 879_CR3
  doi: 10.1101/2023.09.08.556914
– volume: 88
  start-page: 188
  issue: 2–3
  year: 2007
  ident: 879_CR12
  publication-title: Drug Alcohol Depend
  doi: 10.1016/j.drugalcdep.2006.10.014
– volume: 11
  start-page: 5
  year: 2017
  ident: 879_CR22
  publication-title: Trauma Case Rep
  doi: 10.1016/j.tcr.2017.09.002
– volume: 27
  start-page: 442
  issue: 4
  year: 2008
  ident: 879_CR34
  publication-title: Drug Alcohol Rev
  doi: 10.1080/09595230802089701
– volume: 22
  start-page: 187
  issue: 2
  year: 2014
  ident: 879_CR29
  publication-title: Wound Repair Regen
  doi: 10.1111/wrr.12117
– volume: 18
  start-page: 80
  year: 2021
  ident: 879_CR13
  publication-title: Harm Reduct J
  doi: 10.1186/s12954-021-00528-x
– volume: 76
  start-page: 561
  issue: 899
  year: 2000
  ident: 879_CR33
  publication-title: Postgrad Med J
  doi: 10.1136/pmj.76.899.561
– volume: 17
  start-page: 27
  issue: 1
  year: 2020
  ident: 879_CR38
  publication-title: Harm Reduct J
  doi: 10.1186/s12954-020-00372-5
– ident: 879_CR10
  doi: 10.31389/jied.122
– volume: 26
  start-page: 160
  issue: 4
  year: 2013
  ident: 879_CR27
  publication-title: Adv Skin Wound Care
  doi: 10.1097/01.ASW.0000428861.26671.41
– volume: 42
  start-page: 243
  issue: 2
  year: 2019
  ident: 879_CR2
  publication-title: J Vet Pharmacol Ther
  doi: 10.1111/jvp.12724
– volume: 81
  start-page: 428
  issue: 3
  year: 2016
  ident: 879_CR16
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.12731
– ident: 879_CR41
– ident: 879_CR8
– volume: 25
  start-page: 43
  issue: 1
  year: 2001
  ident: 879_CR23
  publication-title: Alcohol Res Health
– ident: 879_CR6
  doi: 10.1016/j.drugalcdep.2008.03.005
– volume: 35
  start-page: 169
  issue: 1
  year: 2021
  ident: 879_CR24
  publication-title: Infect Dis Clin N Am
  doi: 10.1016/j.idc.2020.10.006
– volume: 46
  start-page: 156
  year: 2017
  ident: 879_CR42
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2017.05.050
– volume: 10
  start-page: 571
  issue: 10
  year: 2021
  ident: 879_CR37
  publication-title: Adv Wound Care (New Rochelle)
  doi: 10.1089/wound.2020.1243
– volume: 198
  start-page: 80
  year: 2019
  ident: 879_CR25
  publication-title: Drug Alcohol Depend
  doi: 10.1016/j.drugalcdep.2019.01.037
– volume: 11
  start-page: 295
  issue: 4
  year: 1988
  ident: 879_CR1
  publication-title: J Vet Pharmacol Ther
  doi: 10.1111/j.1365-2885.1988.tb00189.x
– volume: 89
  start-page: 519
  issue: 3
  year: 2012
  ident: 879_CR5
  publication-title: J Urban Health
  doi: 10.1007/s11524-011-9662-6
– volume: 240
  start-page: 1
  year: 2014
  ident: 879_CR4
  publication-title: Forensic Sci Int
  doi: 10.1016/j.forsciint.2014.03.015
– ident: 879_CR19
– volume: 233
  year: 2022
  ident: 879_CR15
  publication-title: Drug Alcohol Depend
  doi: 10.1016/j.drugalcdep.2022.109380
– volume: 191
  start-page: 248
  issue: 2
  year: 2022
  ident: 879_CR39
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwab233
– ident: 879_CR20
  doi: 10.12968/bjon.2018.27.18.1050
– volume: 62
  start-page: 31
  issue: 1
  year: 2015
  ident: 879_CR17
  publication-title: Anesth Prog
  doi: 10.2344/0003-3006-62.1.31
– volume: 49
  start-page: 139
  issue: 2
  year: 2012
  ident: 879_CR35
  publication-title: Braz J Vet Res Anim Sci
  doi: 10.11606/issn.2318-3659.v49i2p139-145
– ident: 879_CR40
– volume: 74
  start-page: 607
  issue: 4
  year: 2016
  ident: 879_CR26
  publication-title: J Am Acad Dermatol
  doi: 10.1016/j.jaad.2015.08.070
– volume: 60
  start-page: 892
  issue: 8
  year: 2022
  ident: 879_CR14
  publication-title: Clin Toxicol
  doi: 10.1080/15563650.2022.2063135
– ident: 879_CR9
– reference: 38012764 - Harm Reduct J. 2023 Nov 27;20(1):170. doi: 10.1186/s12954-023-00903-w.
SSID ssj0029538
Score 2.50207
SecondaryResourceType review_article
Snippet Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine's harm, current knowledge...
Objectives Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine's harm, current...
ObjectivesXylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine’s harm, current...
Abstract Objectives Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine’s harm,...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 141
SubjectTerms Anemia
Anesthesia
Benzodiazepines
Blood pressure
Case reports
Community involvement
Community participation
Complications and side effects
Dosage and administration
Drug injection
Drug withdrawal
Drugs
Epidemiology
Fatalities
Fentanyl
Harm Reduction
Health aspects
Heroin
Humans
Hyperglycemia
Hypertension
Management
Medical personnel
Methods
Narcotics
Poisoning
Public Health
Public participation
Reduction
Sex crimes
Surveillance
Veterinary drugs
Veterinary medicine
Wounds
Xylazine
Xylazine - therapeutic use
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NixUxDA-yJy_it6NvpYLoQYfdaWfa6d5WcVkEPYiLeyv9ZMXHvOW9t6D_vUk783iDoBfn2KYwbZImockvAC9bK7nnx6n26AvUrepT7RqV6hBatF_ae5er-D99lucX7cfL7nKv1RflhBV44HJwR4lLq_vgpAiudf7Y-dBFoYJNyXoRM9g22rwpmBpDLY16PJXI9PJo09BzVo32qSYMNl2rmRnKaP1_3sl7RmmeMLlngc7uwp3RdWSn5Zfvwa043IdFqa9l3-Iy2XVkr9g0sFr_eAD2C0Gzonli6OgxgqnesFViP38tM6z0CZsqI9kELh43b9mIAHTFQiSAiS0O2SGwAonNSukkoyR3vNkfwsXZh6_vz-uxqwKyQ7ZbjDx9DOhl-MB90iJyazFObZRUDkdFFzsMoaTwAhnng5UqNE7LDp1wNO6Jd-IRHAyrIT4BppKzfcuDTEm3nbBa-yAdeii9FGgDdAXNdMjGj5Dj1PliaXLo0UtTGGOQMSYzxqgK3uzWXBfAjb9SvyPe7SgJLDsPoAiZUYTMv0SogtfEeUMqjb_n7ViZgJskcCxzqui5mjr6VLCYUaIq-vn0JDtmvAo2BkNShWGl5H0FL3bTtJLS24a4usk06KkLJKvgcRG13ZaEok_iTD8Twtme5zPD96sMFI6-M3WYE0__xyk9g9s8KxDlyizgYLu-iYfokG3d86x7vwEnuTR-
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEB-0vghS9PxaPSWC6IMu7W12k11fpIqlCPVBrN5byKcVj9329gr63zuTzV67CN3HZAIbJpP5JZn5DcDLUovCFvsht4gF8lLWITcLGXLnSvRfjbUmZvEffxFHJ-XnZbVMF259Cqsc98S4UbvO0h35HiJ7iehcFPX7s_OcqkbR62oqoXETbhF1GYV0yeXlgatBax4TZWqx1y_oUStHL5UTE1uTy4kzipz9_-_MV1zTNGzyih86vAu7CUCyg0Hj9-CGb2dwZ7h9Y0NS0QzmQ9Yt--FXQa89e8XGhm79ewaz7xQEEzNx2XF6XL8P-ivRuKIrYwgKGVFa96wL7M_fVaSgfsfGLEo2EpH7_i1LbEGnzHkio9hgk24dG-iz2ZBmySggHr3AAzg5_PTt41GeKjCg6kS5wVOq9Q4RiXWFDQ33hdZ4pl1IIQ228spXeNwS3HJUsnVaSLcwjagQsCMQCEXFH8JO27X-MTAZjK7LwokQmrLiummsEwbRTC04-osmg8WoCmUTPTlVyVipeEyphRrUp1B9KqpPyQzebMecDeQc10p_IA1vJYlYOzZ0658q2akKhdBN7YzgzpTG7hvrKs-l0yFoy73I4DWtD0Xmj79ndcpiwEkSkZY6kPS0TdV_MphPJNFs7bR7XGEqbRu9ulzkGbzYdtNICoVrfXcRZRDVcxTL4NGwILdT4pI-gT31ZKlO5jztaX-dRlJxxNlUjY4_uf6_nsLtIhoQRczMYWezvvDPEJZtzPNoe_8A24Y1-w
  priority: 102
  providerName: ProQuest
Title Reducing the harms of xylazine: clinical approaches, research deficits, and public health context
URI https://www.ncbi.nlm.nih.gov/pubmed/37777769
https://www.proquest.com/docview/2877499628
https://www.proquest.com/docview/2870993499
https://pubmed.ncbi.nlm.nih.gov/PMC10544173
https://doaj.org/article/f26a98db63db4bc0bcd5e37daffac3e6
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9NAEB_u48UX8dtoLSuIPmj0kk12E0GkJ3cchTvktHhvy356Ykm17cHdf-_MJikXPMS-FHYnbTczk_lNd-c3AC8KLXKb74XUIhZIC1mF1GQypM4VGL9qa02s4j8-EUezYnpWnm1B3-6ou4GrG1M76ic1W87fXv6--ogO_yE6fCXerTLarEox-qTEsFancht2MTJJctTjYrOrgFKxs3VWSJnKMpN9Ec2NnzEIVJHP_--n9rWwNTxSeS1GHd6B2x24ZJPWGu7Clm_uwaitwGXf_DzopWcvWT-wWP68D_qUyFsxgDGEgoyIrFdsEdjl1TwST79nfe0k6-nH_eoN6ziCzpnzREGxxiHdONaSZrO2uJLRMXh89j-A2eHB109Hadd3ARUmijXmptY7xCHW5TbU3OdaYyabSSENjvLSl5hkCW45qtY6LaTLTC1KhOkY_kNe8oew0ywa_xiYDEZXRe5ECHVRcl3X1gmDGKYSHKNEnUDW32RlO1Jy6o0xVzE5qYRqFaNQMSoqRskEXm-u-dVScvxTep90t5EkOu04sFh-V513qpALXVfOCO5MYeyesa70XDodgrbciwRekeYVmSH-PKu72gVcJNFnqYmkDW3q-ZPAaCCJzmqH073tqN7WFSatEhNPkVcJPN9M05V0AK7xi4sog1ieo1gCj1pT2yyJS3oJnKkGRjhY83Cm-XEeqcQRXVMPOv7kP774KdzKo3_QYZkR7KyXF_4ZIrK1GcO2PJNj2J1Mpl-m-L5_cPL5dBz_3xhHF_wDp-M1hg
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB5V2wNICMHyCixgJB4HiNqNEztBQqiFVlvaXaGqLb0Zxw-KWCVldyvon-I3MpPH0gipt-ZoO5KjGc83E898A_A81iIy0boPDfoCYSxTH-ZD6UNrY8SvzJi8quIfT8ToMP50nByvwJ-2FobSKlubWBlqWxr6R76Gnr1E71xE6fvTnyF1jaLb1baFRq0Wu-78F4Zs83c7H1G-L6Joe-vgwyhsugrgdkS8wMjLOIsoa2xkfMZdpDXGaUMpZI6jPHEJhhCCG44bN1YLaYd5JhJ0QhHcfERdItDkr8YcQ5kerG5uTT7vL0O8DO1HW5qTirX5kK7RQsTFkLjfslB24K_qEvA_FlwAw26i5gXk274FNxuXlW3UOnYbVlzRhxv1_z5WlzH1YVDX-bIvbur1zLGXrB0oZz_60D-itJuq9peNm-v8O6D3iTgWwZOhG8qIRHvOSs9-n08r0uu3rK3bZC31uZu_YQ0_0QmzjugvFjikC8tqwm5WF3YySsFH3LkLh1cinXvQK8rCPQAmfa7TOLLC-yxOuM4yY0WO_lMqOCJUFsCwFYUyDSE69eWYqiowSoWqxadQfKoSn5IBvF6-c1rTgVy6epMkvFxJVN7VQDn7phrLoHwkdJbaXHCbx7lZz41NHJdWe68NdyKAV6QfigwObs_opm4CP5Kou9SGpMt06jcUwKCzEg2F6U63GqYaQzVX_45VAM-W0_QmJd8Vrjyr1mAcwXFZAPdrhVx-Epf0CJxJO6ra-ebuTPH9pKIxR8-e-t_xh5fv6ylcGx2M99TezmT3EVyPqsNE-ToD6C1mZ-4xOoWL_ElzEhl8verD_xfDwnI6
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reducing+the+harms+of+xylazine%3A+clinical+approaches%2C+research+deficits%2C+and+public+health+context&rft.jtitle=Harm+reduction+journal&rft.au=Zagorski%2C+Claire+M&rft.au=Hosey%2C+Rebecca+A&rft.au=Moraff%2C+Christopher&rft.au=Ferguson%2C+Aaron&rft.date=2023-09-30&rft.issn=1477-7517&rft.eissn=1477-7517&rft.volume=20&rft.issue=1&rft.spage=141&rft_id=info:doi/10.1186%2Fs12954-023-00879-7&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-7517&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-7517&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-7517&client=summon